Kevin Gade
Kevin Gade is the Chief Operating Officer at Bahl & Gaynor, an investment management firm. He recently gained attention for his comments on Eli Lilly's experimental weight-loss pill, orforglipron, which showed promising results in clinical trials, suggesting that the data bodes well for future trials and market prospects.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Kevin Gade is the chief operating officer at Bahl & Gaynor, which owns Lilly shares.
8
Canada:
Kevin Gade, chief operating officer at Bahl & Gaynor, stated that the data is fantastic from an efficacy standpoint.
9